FDA-Approved Chimeric Antigen Receptor (CAR)-T Cell Therapy for Different Cancers-A Recent Perspective

Thirumalaisamy, R.; Vasuki, S.; Sindhu, S. M.; Mothilal, T. M.; Srimathi, V.; Poornima, B.; Bhuvaneswari, M.; Hariharan, Mohan

doi:10.1007/s12033-024-01090-0

Mol Biotechnol

2024

DOI: 10.1007/s12033-024-01090-0

|View full text |Cite

FDA-Approved Chimeric Antigen Receptor (CAR)-T Cell Therapy for Different Cancers-A Recent Perspective

R. Thirumalaisamy,

S. Vasuki,

S. M. Sindhu

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

In vitro cancer cell line luminescence‐based validation of anticancer phytocompounds obtained from Leucas biflora against HELA cervical and A549 lung cancer cells

Chitra,

Sureshkumar,

Muraleedharan

et al. 2024

Luminescence

View full text Add to dashboard Cite

Current research aims to screen the anticancer prospective of Leucas biflora phytocompounds against apoptotic regulator target protein essential for cancer progression. In gas chromatography–mass spectrometry analysis major phytocompounds such as tetracosahexaene, squalene, phytol, 22‐stigmasten‐3‐one, stigmasterol, fluorene, and 1,4‐dihydro were identified in ethanolic leaf extract of Leucas biflora. In vitro, the free radical scavenging potential of ethanolic leaf extract of Leucas biflora was examined through its DPPH and ABTS radical scavenging potential IC50 value 15.35 and 13.20 μg/ml, respectively. Dose‐dependent cytotoxicity was monitored against both A549 lung cancer and HELA cervical cancer cells. Leucas biflora ethanolic leaf extract highly reduces the cell viability of both HELA and A549 cells in in vitro cytotoxicity assays. Leucas biflora ethanolic extract produces 23.76% and 29.76% viability rates against A549 lung and HELA cervical cancer cell lines, and their IC50 values differ slightly at 95.80 and 90.40 μg/ml, respectively. In molecular docking analysis lung cancer target protein–ligand complex 5Y9T‐16132746 showed a maximum score of −14 kcal/mol by exhibiting stable binding affinity and interactions among all screened complexes. Based on docking score nine phytocompounds from Leucas biflora and two reference standard drugs were chosen for further analysis. Further validation reveals that the fluorene, 1,4‐dihydro possess good ADMET, Bioactivity and density functional theory indices.

show abstract

In vitro cancer cell line luminescence‐based validation of anticancer phytocompounds obtained from Leucas biflora against HELA cervical and A549 lung cancer cells

Chitra,

Sureshkumar,

Muraleedharan

et al. 2024

Luminescence

View full text Add to dashboard Cite

show abstract

Conversion of anti-tissue factor antibody sequences to chimeric antigen receptor and bi-specific T-cell engager format

Saunderson,

Halpin,

Tan

et al. 2024

Cancer Immunol Immunother

View full text Add to dashboard Cite

Background The efficacy of antibody-targeted therapy of solid cancers is limited by the lack of consistent tumour-associated antigen expression. However, tumour-associated antigens shared with non-malignant cells may still be targeted using conditionally activated-antibodies, or by chimeric antigen receptor (CAR) T cells or CAR NK cells activated either by the tumour microenvironment or following 'unlocking' via multiple antigen-recognition. In this study, we have focused on tissue factor (TF; CD142), a type I membrane protein present on a range of solid tumours as a basis for future development of conditionally-activated BiTE or CAR T cells. TF is frequently upregulated on multiple solid tumours providing a selective advantage for growth, immune evasion and metastasis, as well as contributing to the pathology of thrombosis via the extrinsic coagulation pathway. Methods Two well-characterised anti-TF monoclonal antibodies (mAb) were cloned into expression or transposon vectors to produce single chain (scFv) BiTE for assessment as CAR and CD28-CD3-based CAR or CD3-based BiTE. The affinities of both scFv formats for TF were determined by surface plasmon resonance. Jurkat cell line-based assays were used to confirm the activity of the BiTE or CAR constructs. Results The anti-TF mAb hATR-5 and TF8-5G9 mAb were shown to maintain their nanomolar affinities following conversion into a single chain (scFv) format and could be utilised as CD28-CD3-based CAR or CD3-based BiTE format. Conclusion Because of the broad expression of TF on a range of solid cancers, anti-TF antibody formats provide a useful addition for the development of conditionally activated biologics for antibody and cellular-based therapy.

show abstract

Adoptive cell therapy in acute myeloid leukemia: the current landscape and emerging strategies

Tharakan,

Tremblay,

Azzi

2024

Leukemia & Lymphoma

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

FDA-Approved Chimeric Antigen Receptor (CAR)-T Cell Therapy for Different Cancers-A Recent Perspective

Cited by 3 publications

References 68 publications

In vitro cancer cell line luminescence‐based validation of anticancer phytocompounds obtained from Leucas biflora against HELA cervical and A549 lung cancer cells

In vitro cancer cell line luminescence‐based validation of anticancer phytocompounds obtained from Leucas biflora against HELA cervical and A549 lung cancer cells

Conversion of anti-tissue factor antibody sequences to chimeric antigen receptor and bi-specific T-cell engager format

Adoptive cell therapy in acute myeloid leukemia: the current landscape and emerging strategies

Contact Info

Product

Resources

About